Gynecologic Oncology

An association was found between the use of nonsteroidal anti-inflammatory drugs and endometrial cancer risk.

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the next steps to take with pelvic intensity-modulated radiation therapy for patients with gynecological cancers.

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the novel approaches with immunotherapy that he would like to explore in the future treatment of patients with gynecologic cancers.

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.

Oncologists continue to face several challenges when it comes to the prevention and treatment of cervical cancer, according to Michael Birrer, MD, PhD.

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses recent advancements in cervical cancer.

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

Pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.

Regular screening for cervical cancer was found to be associated with an overall mortality prevention rate of 83%.

Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.

Combining the diabetes drug metformin with everolimus and letrozole resulted in a clinical benefit rate of 60% in women with advanced or recurrent endometrioid endometrial cancer.

Vaginal brachytherapy has been linked to improved survival in women with stage I endometrioid adenocarcinoma of the uterus.

Emily M. Ko, MD, discusses the implications of two clinical trial findings for patients with endometrial cancer, and how several risk factors may lead to a surgical treatment delay.

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses why surgery is an effective option for patients with endometrial cancer.

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

The FDA has approved the cobas HPV Test for use with SurePath Preservative Fluid for the detection of human papilloma virus (HPV) in cervical cells.

A new NCCN guideline for the management of vulvar cancer outlines the use of resection, radiation therapy, and chemotherapy based on disease site and stage, recognizing that only 2 randomized treatment trials have been completed.

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.

With technological advancements in genome sequencing, researchers are now gaining a more detailed picture of the genetic drivers of cervical cancer and the important role that the human papillomavirus, responsible for the vast majority of cervical cancer cases, plays in molding the genetic profile of this disease.